Comparison of the analytical and clinical sensitivities of 34 rapid antigen tests with prevalent SARS-CoV-2 variants of concern during the COVID-19 pandemic in the UK

Antigen-detection rapid diagnostic tests (Ag-RDTs) have become a central pillar for the management of coronavirus disease worldwide due to their speed and ease of use and are now being developed for use in other emerging outbreaks. Like other viruses, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is subject to rapid mutation as it spreads, and new variants of concern (VOCs) emerge frequently, posing a significant challenge for the detection of newer, highly mutated variants. It is, therefore, important that the performance of Ag-RDTs is regularly evaluated, particularly in outbreak scenarios where rapid diagnostics are key to limiting disease spread. Here, we present a comprehensive evaluation of the analytical and clinical sensitivities of 34 commercially available Ag-RDTs with five SARS-CoV-2 VOCs, all of which were highly prevalent in the UK at various times between 2019 and 2023. This study highlights the importance of regular evaluation of the Ag-RDT performance, with several Ag-RDTs demonstrating a reduced performance with some VOCs. We conclude that a regular performance evaluation through our proposed pipeline, combined with a broad consensus approval threshold across global organizations, is essential to maintaining the effectiveness of Ag-RDTs as a disease management tool during outbreaks.